Once an organization has identified, categorized, and scored its corporate risk portfolio, it must deploy a systematic process to bring its exposures into full alignment with board-approved appetite boundaries. This process is governed by the Core Risk Treatment Hierarchy.

Rather than allowing individual department managers to react randomly to operational threats, the enterprise risk management framework mandates an objective evaluation of four distinct treatment pathways: Risk Avoidance, Risk Reduction, Risk Sharing, and Risk Acceptance. Selecting the appropriate path requires a disciplined review of the risk’s velocity, its potential to cause compounding failures across separate divisions, and the financial capital available to support mitigation.

The final selection of a risk treatment pathway cannot be made in isolation; it must be approved by the board’s risk committee through formal Treatment Financing Governance. Management must present clear business cases that contrast the long-term capital required to fund a treatment strategy against the expected financial protection achieved.

By requiring the C-suite to explicitly prove that proposed treatments optimize the corporate risk-return frontier, the board ensures that risk reduction capital is deployed efficiently and does not create unnecessary operational friction that harms shareholder value.